Bpco, AstraZeneca: "Tozorakib Reduces Exacerbations by 30%"
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.6 Articles
6 Articles
Il Tempo
Rome, 11 Sep. (Adnkronos Salute) - Bpco (Chronic obstructive Broncopneumopathy) in Italy hits about 2.2 million people and represents the third cause of death globally. "For patients, however, there is an important novelty, represented by tozorakib, molecule arrived to phase III studies Oberon and Titania with unprecedented results," presented at the 2026 congress of the European Respiratory Society, just carried out in Barcelona. It is stated a…
Rec News | Lontani dal mainstream
notizie.itIn Italy, Bpco (Chronic obstructive Broncopneumopathy) affects about 2.2 million people and represents the third cause of death globally. For patients, however, there is an important novelty, represented by tozorakib, molecule arrived at the phase III studies Oberon and Titania with unprecedented results, presented at the congress 2026 [...] The article Bpco, AstraZeneca: Tozorakib reduces the exacerbations by 30% from Rec News.
Coverage Details
Bias Distribution
- 100% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
